The Research Group in Immunology and Metabolism (GRIM) is subdivided into 2 nodes that represent the basic and clinical research of the group.
Basic node: Immunology and Immunopathology Group (GRIIP)
The GRIIP is the basic research node of the Research Group in Immunology and Metabolism (GRIM).The group of the University of Lleida (UdL) and the Institute of Biomedical Research of Lleida (IRBLleida) is currently constituted by two Principal Investigators, Joan Verdaguer and Concepció Mora, and their respective research units. Both investigators have a long history as leading researchers in R & D for more than a decade and a half in the field of immunology and autoimmunity. Both researchers are members of the same research group recognized by the Generalitat (SGR) of the UdL and IRBLleida since its inception.
The research objective of the group is the study of the mechanisms of loss of immunological tolerance in autoimmune endocrine diseases, and more specifically in Type 1 Diabetes (T1D), and in the study of tools for the diagnosis and treatment of these diseases. The group also aims to lay the foundations on a future immunotherapy of T1D and other endocrinopathies of autoimmune origin, through participation and collaboration with different research and care groups.
Clinical node: Obesity, Diabetes and Metabolism Research Group (ODIM)
The ODIM is the clinical research node of the Immunology and Metabolism Research Group (GRIM). The main lines of research of the Group are organized around 4 main branches:
- Morbid obesity and its comorbidities, with great interest in the development of personalized medicine, based on:
- The genetic propensity to develop comorbidities such as non-alcoholic fatty liver, apnea syndrom or type 2 diabetes mellitus.
- The ability to predict comorbidity resolution and weight loss after bariatric surgery.
- The study of cellular and molecular signaling mechanisms involved in the cellular response to insulin, initially focused on the characterization of PKRN1 phosphokinase.
- Deepen the study of cardiovascular disease in the "other" diabetes: diabetes mellitus type 1, diabetes type LADA, and monogenic diabetes.
- Confirmation that the lung is the target organ of late complications of type 2 diabetes mellitus.
Rodriguez-Fernandez S; Pujol-Autonell I; Brianso F; Perna-Barrull D; Cano-Sarabia M; Garcia-Jimeno S; Villalba A; Sanchez A; Aguilera E; Vazquez F; Verdaguer J; Maspoch D; Vives-Pi M
Phosphatidylserine-liposomes promote tolerogenic features on dendritic cells in human type 1 diabetes by apoptotic mimicry
Frontiers in Immunology 9 253-253. .
Goday, A.; Barneto, I.; GarcÃa-Almeida, J.M.; Blasco, A.; Lecube, A.; GrÃ¡valos, C.; MartÃnez de Icaya, P.; de Las PeÃ±as, R.; Monereo, S.; VÃ¡zquez, L.; Palacio, J.E.; PÃ©rez-Segura, P.
Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology
CLINICAL & TRANSLATIONAL ONCOLOGY 17 763-771. .